BioVaxys expands patent coverage on CoviDTH by filing international patent application through PCT

BioVaxys Technology Corp. (BioVaxys) announced that it has broadened the patent coverage on CoviDTH, its T cell diagnostic for detecting an immune response to SARS-CoV-2, by filing an international patent application through the Patent Cooperation Treaty (PCT) for broad geographic market coverage outside the US. Although CoviDTH diagnostic results are intended to be visually interpreted by a trained technician or healthcare provider, additional patent claims include data capture and analysis via methods such as optical, infrared, and ultrasonic image processing. The International Patent Cooperation Treaty (PCT) Application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. BioVaxys recently also filed international applications for registration of the CoviDTH trademark in selected markets including Canada, Mexico, European Union and United Kingdom. Six months ago, the Company filed its application with the United States Patent and Trademark Office (USPTO) for US registration of its "CoviDTH" trademark. Trademark applications in certain countries may be treated as if they had been filed on the filing date of the US application, provided the applications are filed within six months of the US filing date. BioVaxys may still apply for trademark registration of CoviDTH in other countries at a later date, but it will be without the benefit of the earlier US filing date. BioVaxys CEO James Passin states, "Given the urgent importance of commercializing a low-cost diagnostic for T cell immunity to Covid-19 in the context of the global pandemic, we believe that it critical to protect Intellectual Property in key international markets as we continue to advance to towards the submission of an IND in the United States." For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time. Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!